Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
110 participants
INTERVENTIONAL
2008-04-30
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
EPO
Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI
2
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EPO
Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Infarct related artery : proximal circumflex artery , proximal and mid left anterior descending artery, 1st segment of the right coronary artery
* TIMI 0 or 1 before angioplasty
* Successful PCI defined by residual stenosis \< 50% and TIMI 2 or 3 flow grade
* Body weight : \[50-110\] kg
* Informed, written consent
Exclusion Criteria
* Pregnant, or parturient or breast-feeding women;
* Sexually active women without efficient contraception;
* Inability to fully cooperate with the study protocol
* Pre-treatment with fibrinolysis ;
* Previous Q-wave myocardial infarction or previous aorto-coronary bypass;
* History of deep vein thrombosis or pulmonary embolism;
* Contraindication to aspirin or clopidogrel ;
* Cardiogenic shock ;
* Cardiac resuscitated before angioplasty ;
* Past or active erythropoietin therapy;
* Contraindications to erythropoietin therapy: uncontrolled hypertension, known hypersensitivity to benzoic acid, chronic liver insufficiency, hemoglobin\> 16g / l, thrombocytosis, refractory anemia with excess of blasts;
* Renal insufficiency (creatinine clearance \<30ml/mn.);
* Active Malignancies
* Any contraindications to magnetic resonance imaging: pacemaker and automatic cardiac defibrillator, hearing aid, neurostimulator, infusion pump etc metallic splinters in the eye, ferromagnetic haemostatic clips in the central nervous system cochlear implants, claustrophobia;
* Allergy to gadolinium ;
* Patient refusal / patient not having provided written informed consent.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fédération Française de Cardiologie
OTHER
Société Française de Cardiologie
OTHER
University Hospital, Angers
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University Hospital, Angers
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fabrice PRUNIER, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Angers
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Angers
Angers, , France
Fabrice PRUNIER, MD, PhD,
Angers, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Prunier F, Biere L, Gilard M, Boschat J, Mouquet F, Bauchart JJ, Charbonnier B, Genee O, Guerin P, Warin-Fresse K, Durand E, Lafont A, Christiaens L, Abi-Khalil W, Delepine S, Benard T, Furber A. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial. Am Heart J. 2012 Feb;163(2):200-7.e1. doi: 10.1016/j.ahj.2011.11.005.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PHRC 2007-03
Identifier Type: -
Identifier Source: org_study_id